Massimo Fioranelli

Prof. Massimo Fioranelli


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Massimo FioranelliMassimo Fioranelli
Massimo Fioranelli
ABAnna G. Bottaccioli
Anna G. Bottaccioli
FBFrancesco Bottaccioli
Francesco Bottaccioli
MBMaria Bianchi
Maria Bianchi
MRMiriam Rovesti
Miriam Rovesti
MRMaria G. Roccia
Maria G. Roccia
Recent findings have deeply changed the current view of coronary heart disease, going beyond the simplistic model of atherosclerosis as a passive process involving cholesterol build-up in the subintimal space of the arteries until their final occlusion and/or thrombosis and instead focusing on the key roles of inflammation and the immune system in plaque formation and destabilization. Chronic inflammation is a typical hallmark of cardiac disease, worsening outcomes irrespective of serum cholesterol levels. Low-grade chronic inflammation correlates with higher incidence of several non-cardiac diseases, including depression, and chronic depression is now listed among the most important cardiovascular risk factors for poor prognosis among patients with myocardial infarction. In this review, we include recent evidence describing the immune and endocrine properties of the heart and their critical roles in acute ischaemic damage and in post-infarct myocardial remodeling. The importance of the central and autonomic regulation of cardiac functions, namely, the neuro-cardiac axis, is extensively explained, highlighting the roles of acute and chronic stress, circadian rhythms, emotions and the social environment in triggering acute cardiac events and worsening heart function and metabolism in chronic cardiovascular diseases. We have also included specific sections related to stress-induced myocardial ischaemia measurements and stress cardiomyopathy. The complex network of reciprocal interconnections between the heart and the main biological systems we have presented in this paper provides a new vision of cardiovascular science based on psychoneuroendocrineimmunology.

Verified
Journal Article
Open access
PDF file
Massimo FioranelliMassimo Fioranelli
Massimo Fioranelli
Maria Grazia RocciaMaria Grazia Roccia
Maria Grazia Roccia
DFDana Flavin
Dana Flavin
LCLinda Cota
Linda Cota
Inflammation is a key mechanism for the clearance of infective agents and other inflammatory triggers and is pivotal for the repairing processes of the affected tissues. Inflammation is a multistep process driven by a great number of mediators which regulate specific aspects of the inflammatory response, in agreement with a well-defined chronobiological program. A great number of inflammation-related diseases show a deeply altered immune chronobiology (e.g., COVID-19-related cytokines storm). This aspect highlights the need for a deeper understanding of the inflammatory phenomenon. It is fundamental to study inflammation as a multilevel phenomenon. Of particular interest is the low-grade chronic inflammation, which is an etiological factor of many chronic diseases. Nowadays, the therapeutic approach to low grade chronic inflammation is one of the great challenges of traditional pharmacology. Currently, no drugs specifically designed for the treatment of chronic inflammatory forms are available. Today, bioregulatory systems medicine (BrSM) and low dose medicine (LDM), two pharmacological paradigms grounded in systems medicine, potentially represent new tools for the treatment of inflammation-related diseases. Scientific research has assessed the effectiveness and safety of both these therapeutic approaches, in particular for the management of chronic inflammatory conditions and chronic immunological dysregulations.

1 May 1999 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
Massimo FioranelliMassimo Fioranelli
Massimo Fioranelli
MPM. Piccoli
M. Piccoli
GMG.M. Mileto
G.M. Mileto
FSF. Sgreccia
F. Sgreccia
PAP. Azzolini
P. Azzolini
APA. Puglisi
A. Puglisi

15 March 2017 in Wiener Medizinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
Katlein FrançaKatlein França
Katlein França
AKAnagha Kumar
Anagha Kumar
Massimo FioranelliMassimo Fioranelli
Massimo Fioranelli
TLTorello Lotti
Torello Lotti
MTMichael Tirant
Michael Tirant
MRMaria Grazia Roccia
Maria Grazia Roccia

30 August 2019 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
JSJacopo Scala
Jacopo Scala
AVAleksandra Vojvodic
Aleksandra Vojvodic
PVPetar Vojvodic
Petar Vojvodic
TVTatjana Vlaskovic-Jovicevic
Tatjana Vlaskovic-Jovicevic
ZPZorica Peric-Hajzler
Zorica Peric-Hajzler
TLTorello Lotti
Torello Lotti
Botulinum toxin (BTX) is a neurotoxin derived from the Clostridium botulinum bacterium that inhibits the release of acetylcholine at the neuromuscular junction level whose effects has been used for many years to treat a variety of muscular/neuromuscular conditions and more recently also for cosmetic use. BTX has experimented in some dermatological conditions, which include Rosacea and facial flushing treatment with good results. The complex mechanism underlying those results is not completely understood but was proposed a release inhibition of acetylcholine from peripheral autonomic nerves of the cutaneous vasodilatory system combined with the blockade substance P and calcitonin gene-related peptide (CGRP) thus modulating blood vessel dilatation. We analysed the published data on BTX off label applications rosacea and flushing retrieved from PubMed.

30 August 2019 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
GDGorica Djokic
Gorica Djokic
PVPetar Vojvodic
Petar Vojvodic
DKDavor Korcok
Davor Korcok
AAAnita Agic
Anita Agic
ARAnica Rankovic
Anica Rankovic
TLTorello Lotti
Torello Lotti
Insomnia means difficulty in falling asleep and/or stays asleep. Insomnia commonly leads to daytime sleepiness, lethargy, and a general feeling of being unwell. The most common treatment of insomnia includes GABAA receptor positive allosteric modulators or Melatonin agonists. Our study aimed to evaluate the efficacy of Magnesium- melatonin-vitamin B complex supplement in the treatment of insomnia. The study included 60 patients diagnosed with insomnia. The patients were randomly divided into study group (N = 30), and control group (N = 30), and study group was treated with Magnesium-melatonin-vitamin B complex (one dose contains 175 mg liposomal magnesium oxide, 10 mg Vit B6, 16 μg vit B12, melatonin 1 mg, Extrafolate-S 600 μg) once a day 1 hour before sleep, during the 3 months. The severity of insomnia symptoms was measured by self-reported Athens insomnia scale (AIS), with a cut-off score by Soldatos (AIS score ≥ 6). Mean AIS score at zero points was 14,93 ± 3,778 in the study group and 14,37 ± 4,081 in the control group (p = 0,476), indicating the compatibility of the groups, and both scores correspond to mild to moderate insomnia. Mean AIS score after 3 months of the Magnesium- melatonin- vitamin B complex supplementation was 10,50 ± 4,21 corresponding to mild insomnia, while median AIS score in the control group was 15,13 ± 3,76 which is referred to moderate insomnia, and difference among groups was significant (p = 0,000). Our founding’s indicating that 3 months of the Magnesium- melatonin-vitamin B complex supplementation has a beneficial effect in the treatment of insomnia regardless of cause.